Ana Cristina Medeiros-Ribeiro

Ana Cristina Medeiros-Ribeiro

Auto-generated profile, based on publicly available information

Ana Cristina Medeiros-Ribeiro

Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2013 in Arthritis Care & Research
Verified
Journal Article
Closed access
PDF file
ARAna C. Ribeiro
Ana C. Ribeiro
ILIeda M. Laurindo
Ieda M. Laurindo
LGLissiane K. Guedes
Lissiane K. Guedes
CSCarla G. Saad
Carla G. Saad
JMJulio C. Moraes
Julio C. Moraes
EBEloisa Bonfa
Eloisa Bonfa

1 September 2010 in Biologicals
Verified
Journal Article
Closed access
BSBárbara Santos Pires da Silva
Bárbara Santos Pires da Silva
EBEloísa Bonfá
Eloísa Bonfá
JMJúlio César Bertacini de Moraes
Júlio César Bertacini de Moraes
CSCarla Gonçalves Schain Saad
Carla Gonçalves Schain Saad
ARAna Cristina de Medeiros Ribeiro
Ana Cristina de Medeiros Ribeiro
JCJozélio De Carvalho
Jozélio De Carvalho

26 July 2023 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
KBKarina Rossi Bonfiglioli
Karina Rossi Bonfiglioli
ARAna Cristina de Medeiros Ribeiro
Ana Cristina de Medeiros Ribeiro
ACAna Paula Carnieletto
Ana Paula Carnieletto
IPIvânio Pereira
Ivânio Pereira
DDDiogo Souza Domiciano
Diogo Souza Domiciano
GCGeraldo da Rocha Castelar-Pinheiro
Geraldo da Rocha Castelar-Pinheiro
Introduction: Although Rheumatoid Arthritis (RA) extra-articular manifestations (ExtRA) occurrence has been decreasing over time, they are still a major mortality risk factor for patients. Objective: To determine the prevalence of ExtRA in a large cohort, and its association with demographic and clinical variables. Method: Cross-sectional and observational study, based on a multi-centric database from a prospective cohort, in which 11 public rheumatology centres enrolled RA patients (1987 ARA or 2010 ACR-EULAR). Data collection began in 08-2015, using a single online electronic medical record. Continuous variables were compared using Mann–Whitney U-test, and Fisher’s exact test or chi-square test, as appropriate, were used for categorical variables. The level of significance was set at 5% (p < 0.05). Results: 1115 patients were included: 89% women, age [mean ± SD] 58.2 ± 11.5 years, disease duration 14.5 ± 12.2 years, positive Rheumatoid Factor (RF, n = 1108) in 77%, positive anti-cyclic citrullinated peptide (ACPA, n = 477) in 78%. Regarding ExtRA, 334 occurrences were registered in 261 patients, resulting in an overall prevalence of 23.4% in the cohort. The comparison among ExtRA and Non-ExtRA groups shows significant higher age (p < 0.001), disease duration (p < 0.001), RF high titers (p = 0.018), Clinical Disease Activity index (CDAI) (p < 0.001), Disease Activity Index 28 (DAS 28) (p < 0.001), and Health Assessment Questionnaire (HAQ) (p < 0.001) in ExtRA group. Treatment with Azathioprine (p = 0.002), Etanercept (p = 0.049) Glucocorticoids (GC) (‘p = 0.002), and non-steroidal anti-inflammatory drugs (NSAIDs) (p < 0.001) were more frequent in ExtRA group. Conclusions: ExtRA manifestations still show an expressive occurrence that should not be underestimated. Our findings reinforce that long-term seropositive disease, associated with significant disability and persistent inflammatory activity are the key factors related to ExtRA development.

30 August 2020 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
LALisbeth A. Aguila
Lisbeth A. Aguila
HSHenrique Carriço da Silva
Henrique Carriço da Silva
AMAna Cristina Medeiros-Ribeiro
Ana Cristina Medeiros-Ribeiro
BBBruna Giusto Bunjes
Bruna Giusto Bunjes
ALAna Paula Luppino-Assad
Ana Paula Luppino-Assad
PSPercival D. Sampaio-Barros
Percival D. Sampaio-Barros

20 May 2022 in Lupus
Verified
Journal Article
Open access
FSFlavio Signorelli
Flavio Signorelli
GBGustavo Guimarães Moreira Balbi
Gustavo Guimarães Moreira Balbi
NANadia E Aikawa
Nadia E Aikawa
CSClovis A Silva
Clovis A Silva
LKLéonard de Vinci Kanda Kupa
Léonard de Vinci Kanda Kupa
EBEloisa Bonfá
Eloisa Bonfá
Objective: Coronavirus disease 19 (COVID-19) has an increased risk of coagulopathy with high frequency of antiphospholipid antibodies (aPL). Recent reports of thrombosis associated with adenovirus-based vaccines raised concern that SARS-CoV-2 immunization in primary antiphospholipid syndrome (PAPS) patients may trigger clotting complications. Our objectives were to assess immunogenicity, safety, and aPL production in PAPS patients, after vaccinating with Sinovac-CoronaVac, an inactivated virus vaccine against COVID-19. Methods: This prospective controlled phase-4 study of PAPS patients and a control group (CG) consisted of a two-dose Sinovac-CoronaVac (D0/D28) and blood collection before vaccination (D0), at D28 and 6 weeks after second dose (D69) for immunogenicity/aPL levels. Outcomes were seroconversion (SC) rates of anti-SARS-CoV-2 S1/S2 IgG and/or neutralizing antibodies (NAb) at D28/D69 in naïve participants. Safety and aPL production were also assessed. Results: We included 44 PAPS patients (31 naïve) and 132 CG (108 naïve) with comparable age ( p=0.982) and sex ( p>0.999). At D69, both groups had high and comparable SC (83.9% vs. 93.5%, p=0.092), as well as NAb positivity (77.4% vs. 78.7%, p=0.440), and NAb-activity (64.3% vs. 60.9%, p=0.689). Thrombotic events up to 6 months or other moderate/severe side effects were not observed. PAPS patients remained with stable aPL levels throughout the study at D0 vs. D28 vs. D69: anticardiolipin (aCL) IgG ( p=0.058) and IgM ( p=0.091); anti-beta-2 glycoprotein I (aβ2GPI) IgG ( p=0.513) and IgM ( p=0.468). Conclusion: We provided novel evidence that Sinovac-CoronaVac has high immunogenicity and safety profile in PAPS. Furthermore, Sinovac-CoronaVac did not trigger thrombosis nor induced changes in aPL production.

29 November 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
ATAdriana Coracini Tonacio
Adriana Coracini Tonacio
TPTatiana Do Nascimento Pedrosa
Tatiana Do Nascimento Pedrosa
EBEduardo Ferreira Borba
Eduardo Ferreira Borba
NANadia Emi Aikawa
Nadia Emi Aikawa
SPSandra Gofinet Pasoto
Sandra Gofinet Pasoto
EBEloisa Bonfá
Eloisa Bonfá
Background: Brazil faced a yellow fever(YF) outbreak in 2016–2018 and vaccination was considered for autoimmune rheumatic disease patients(ARD) with low immunosuppression due to YF high mortality. Objective: This study aimed to evaluate, prospectively for the first time, the short-term immunogenicity of the fractional YF vaccine(YFV) immunization in ARD patients with low immunossupression. Methods and Results: A total of 318 participants(159 ARD and 159 age- and sex-matched healthy controls) were vaccinated with the fractional-dose(one fifth) of 17DD-YFV. All subjects were evaluated at entry(D0), D5, D10, and D30 post-vaccination for clinical/laboratory and disease activity parameters for ARD patients. Post-vaccination seroconversion rate(83.7%vs.96.6%, p = 0.0006) and geometric mean titers(GMT) of neutralizing antibodies[1143.7 (95%CI 1012.3–1292.2) vs.731 (95%CI 593.6–900.2), p0.05). Conclusion: Fractional-dose 17DD-YF vaccine in ARD patients resulted in a high rate of seroconversion rate(>80%) but lower than controls, with a longer but less intense viremia. This vaccine was immunogenic, safe and did not induce flares in ARD under low immunosuppression and may be indicated in YF outbreak situations and for patients who live or travel to endemic areas. Trial registration: This clinical trial was registered with Clinicaltrials.gov (#NCT03430388).